AUPH Aurinia Pharmaceuticals Inc
NewsSee all news
-
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
- Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified
-
Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments
University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion
-
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
- Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential
-
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
- Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing
-
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions,
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
- Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified
-
Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments
University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion
-
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
- Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential
-
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
- Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing
-
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions,
-
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
- Data support differentiation of voclosporin as a potential best-in-class CNI - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused
-
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes. Aurinia's
-
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
- Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical
-
Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global
-
Aurinia Establishes At-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has
-
Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C.